Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?

  • Review
  • Published:
Journal of Radiation Oncology

Abstract

Objective

High-grade neuroendocrine carcinomas (HGNECs) of the lung represent a heterogeneous group of poorly differentiated neoplasms and include large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). The development of brain metastases (BMs) occurs in roughly 20% of patients at diagnosis and represents a major issue in the management of HGNECs. The aim of this review is to briefly summarize current knowledge on the therapeutic options to treat lung HGNECs-derived BMs touching upon the unsolved issues of current treatment approaches and the future perspectives in the management of CNS-metastatic HGNECs of the lung.

Methods

We searched MEDLINE and OVID databases for articles in English published from January 1980 to September 2016.

Results

SCLCs and LCNECs share clinical characteristics and biological behavior, as well as major genetic alterations. Consistently, SCLC-like chemotherapy appears to be more effective in LCNECs as compared to NSCLC-like regimens. However, the role of transthoracic radiotherapy and prophylactic cranial irradiation (PCI) is much less studied in LCNECs. Available data might suggest to approach LCNECs patients in a similar way to SCLCs also when it comes to thoracic radiotherapy and PCI.

Conclusion

The development of brain metastasis is associated with poor prognosis and shortened survival in patients with HGNECs. Conventional cytotoxic agents display limited efficacy against HGNECs-derived brain metastasis. Patient with limited or extensive SCLC who respond to chemotherapy benefits from PCI. In LCNECs, the use of PCI is not well defined and might potentially improve the outcome of these patients. Prospective clinical trials addressing this issue are urgently needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Travis W, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB et al (2015) The 2015 World Health Organization classification of lung tumors impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260

    Article  PubMed  Google Scholar 

  2. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S et al (2004) Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363:775–781

    Article  CAS  PubMed  Google Scholar 

  3. Schnabel PA, Junker K (2015) Pulmonary neuroendocrine tumors in the new WHO 2015 classification: start of breaking new grounds? Pathologe 36(3):283–292

    Article  CAS  PubMed  Google Scholar 

  4. Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ et al (2016) Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer 17(5):e121–e129

    Article  PubMed  Google Scholar 

  5. Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M et al (2016) Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol 37(6):7047–7057

    Article  CAS  PubMed  Google Scholar 

  6. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G et al (2005) Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR alpha, PDGFR beta, and met in large-cell neuroendocrine carcinoma of the lung. J Clini Oncol 23:8774–8785

    Article  CAS  Google Scholar 

  7. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30

    Article  PubMed  Google Scholar 

  8. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T et al (2008) Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092–6096

    Article  CAS  PubMed  Google Scholar 

  9. Schultheis AM, Bos M, Schmitz K, Wilsberg L, Binot E, Wolf J et al (2014) Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod Pathol 27:214–221

    Article  CAS  PubMed  Google Scholar 

  10. Arcaro A (2015) Targeted therapies for small cell lung cancer: where do we stand? Crit Rev Oncol Hematol 95(2):154–164

    Article  PubMed  Google Scholar 

  11. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F (2015) Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol 10(8):1133–1141

    Article  PubMed  PubMed Central  Google Scholar 

  12. Available at: http://www.nccn.org/professionals/physician gls/pdf/sclc.pdf. Last accessed 13 Dec 2016

  13. Seute T, Leffers P, ten Velde GP, Twijnstra A (2004) Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 100:801–806

    Article  PubMed  Google Scholar 

  14. Arriagada R, Le Chevalier T, Rivière A, Chomy P, Monnet I, Bardet E et al (2002) Patterns of failure after prophylactic cranial irradiation in small cell lung cancer: analysis of 505 randomized patients. Ann Oncol 13:748–754

    Article  CAS  PubMed  Google Scholar 

  15. El-Sharouni S, Kal HB, Barten-Van Rijbroek A, Struikmans H, Battermann JJ, Schramel FM (2009) Concurrent versus sequential chemotherapy in limited disease small cell lung cancer: a retrospective comparative study. Anticancer Res 29:5219–5224

    CAS  PubMed  Google Scholar 

  16. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845

    Article  PubMed  Google Scholar 

  17. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P (2007) Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 33:461–473

    Article  PubMed  Google Scholar 

  18. Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R (2016) Therapies in the pipeline for small-cell lung cancer. Br Med Bull 119(1):37–48

    Article  PubMed  Google Scholar 

  19. Kudoh S, Fujiwara Y, Takada Y et al (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068–1074

    Article  CAS  PubMed  Google Scholar 

  20. Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

    Article  CAS  PubMed  Google Scholar 

  21. Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810–1816

    Article  CAS  PubMed  Google Scholar 

  22. Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G et al (2015) Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin Lung Cancer 16(6):e223–e228

    Article  CAS  PubMed  Google Scholar 

  23. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G et al (2006) Phase III trial comparing supportive care alone versus supportive care plus oral topotecan in patients with relapsed small cell lung cancer. J Clin Oncol 24:5441–5447

    Article  PubMed  Google Scholar 

  24. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667

    Article  Google Scholar 

  25. Paglialunga L, Salih Z, Ricciuti B, Califano R (2016) Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open 1(4):e000022

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zacharias J, Nicholson AG, Ladas GP, Goldstraw P (2003) Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 75:348–352

    Article  PubMed  Google Scholar 

  27. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K et al (2006) Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 82:1802–1807

    Article  PubMed  Google Scholar 

  28. Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T et al (2009) Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg 138:446–453

    Article  PubMed  Google Scholar 

  29. Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y et al (2010) Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 68:438–445

    Article  PubMed  Google Scholar 

  30. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK et al (2012) Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 77:365–370

    Article  PubMed  Google Scholar 

  31. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H et al (2013) Multicentre phase II study of cisplatin- etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol 24:1548–1552

    Article  CAS  PubMed  Google Scholar 

  32. Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M et al (2013) Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol 8:980–984

    Article  CAS  PubMed  Google Scholar 

  33. Komatsu T, Kunieda E, Oizumi Y, Tamai Y, Akiba T (2013) Clinical characteristics of brain metastases from lung cancer according to histological type: pretreatment evaluation and survival following whole-brain radiotherapy. Mol Clin Oncol 1:692–698

    PubMed  PubMed Central  Google Scholar 

  34. Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM et al (2009) Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 27:78–84

    Article  PubMed  Google Scholar 

  35. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer incomplete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–484

    Article  CAS  PubMed  Google Scholar 

  36. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672

    Article  CAS  PubMed  Google Scholar 

  37. Abratt RP, de Groot M, Willcox PA (1995) Resection of a solitary brain metastasis in a patient with small cell lung cancer: long-term survival. Eur J Cancer 31A:419

    Article  CAS  PubMed  Google Scholar 

  38. Imai R, Hayakawa K, Sakurai H, Nakayama Y, Mitsuhashi N, Niibe H (2011) Small cell lung cancer with a brain metastasis controlled for 5 years: a case report. Jpn J Clin Oncol 31(3):116–118

    Article  Google Scholar 

  39. Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N et al (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869

    Google Scholar 

  40. Wegner RE, Olson AC, Kondziolka D, Niranjan A, Lundsford LD, Flickinger JC (2011) Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. Int J Radiat Oncol Biol Phys 81(3):e21–e27

    Article  PubMed  Google Scholar 

  41. Yomo S, Hayashi M (2015) Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients. BMC Cancer 15:95

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ricciuti B, Metro G, Ferolla P, Chiari R, Paglialunga L, Perrone L et al (2015) Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Ann Oncol 26:78

    Article  Google Scholar 

  43. Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D et al (2016) Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: implications for clinical practice. Lung Cancer 95:82–87

    Article  PubMed  Google Scholar 

  44. Steward DJ (1994) A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 20:121–139

    Article  Google Scholar 

  45. Donelli MG, Zucchetti M, D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251–260

    Article  CAS  PubMed  Google Scholar 

  46. Seute T, Leffers P, Wilmink JT, ten Velde GP, Twijnstra A (2006) Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 24(13):2079

    Article  CAS  PubMed  Google Scholar 

  47. Humblet Y, Weynants P, Bosly A, Majois F, Duprez P, Francis C et al (1989) Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small-cell lung cancer: a dose escalation study of carboplatin. Med Oncol Tumor Pharmacother 6:207–212

    CAS  PubMed  Google Scholar 

  48. Malacarne P, Santini A, Maestri A (1996) Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53:210–213

    Article  CAS  PubMed  Google Scholar 

  49. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D (2008) Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer 9(1):35–38

    Article  CAS  PubMed  Google Scholar 

  50. Twelves CJ, Souhami RL, Harper PG, Ash CM, Spiro SG, Earl HM et al (1990) The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 61(1):147–150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kristjansen PE, Soelberg Sørensen P, Skov Hansen M, Hansen HH (1993) Prospective evaluation of the effect on initial brain metastases from small-cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating drug regimen. Ann Oncol 4:579–583

    Article  CAS  PubMed  Google Scholar 

  52. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK (1989) Primary chemotherapy of brain metastasis in small cell lung cancer. J Clin Oncol 7:916922

    Google Scholar 

  53. Groen HJM, Smit EF, Haaxma-Reiche H, Postmus PE (1993) Carboplatin as second-line treatment for recurrent or progressive brain metastases from small-cell lung cancer. Eur J Cancer 12:1696–1699

    Article  Google Scholar 

  54. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S et al (1993) TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15:1063–1070

    Article  Google Scholar 

  55. Postmus PE, Smit EF, Haaxma-Reiche H, van Zandwijk N, Ardizzoni A, Quoix E et al (1995) Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 13(3):660–665

    Article  CAS  PubMed  Google Scholar 

  56. Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T et al (2000) Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18(19):3400–3408

    Article  CAS  PubMed  Google Scholar 

  57. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK et al (2012) Phase II trial of temozolomide in patients with replapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as potential biomarker. Clin Cancer Res 18(4):1138–1145

    Article  CAS  PubMed  Google Scholar 

  58. Postmus PE, Haaxma-Reiche H, Vencken LM, Meinesz AF, Sleijfer DT, Mulder NH (1989) High dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br J Cancer 59:254–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kleisbauer JP, Vesco D, Orehek J, Blaive B, Clary C, Poirier R et al (1998) Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Franais Pneumo-Cancérologie. Eur J Cancer Clin Oncol 24(2):131–135

    Article  Google Scholar 

  60. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF et al (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12(10):2022–2034

    Article  CAS  PubMed  Google Scholar 

  61. Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S et al (2015) Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother 16(17):2601–2613

    Article  CAS  PubMed  Google Scholar 

  62. Jamal-Hanjani M, Spicer J (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18:938–944

    Article  CAS  PubMed  Google Scholar 

  63. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M et al (2015) Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10:156–163

    Article  CAS  PubMed  Google Scholar 

  64. Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X et al. (2016) Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 34 (suppl; abstr 9002)

  65. Ricciuti B, Chiari R, Chiarini P, Crinò L, Maiettini D, Ludovini V et al (2016) Osimertinib (AZD9291) and CNS response in two radiotherapy-naïve patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig 36(8):683–686

    Article  CAS  PubMed  Google Scholar 

  66. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Kim DW, Mehra R, Tan DS, Felip E, Chow LQM, Ross Camidge R et al. (2014). Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. J Clin Oncol 32(Suppl 5):abstract 8003

  68. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128

    Article  CAS  PubMed  Google Scholar 

  69. Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, West HJ et al. (2015) A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol 33(Suppl):abstract 8019

  70. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes BGM et al. (2015) Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol 33(Suppl):abstract 8008

  71. Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp LK, Pluzanski A et al. (2016) Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). J Clin Oncol 34(suppl; abstr 9038)

  72. Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K et al. (2016) PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC). J Clin Oncol 34(suppl; abstr 8563)

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1-06156, Perugia, Italy

    Biagio Ricciuti, Marta Brambilla, Andrea De Giglio, Giulio Metro, Roberta Porreca, Rita Chiari & Luca Paglialunga

Authors
  1. Biagio Ricciuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Brambilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea De Giglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulio Metro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberta Porreca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rita Chiari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luca Paglialunga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Biagio Ricciuti.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ricciuti, B., Brambilla, M., De Giglio, A. et al. Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. J Radiat Oncol 6, 11–19 (2017). https://doi.org/10.1007/s13566-017-0293-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-017-0293-8

Keywords

Search

Navigation